Literature DB >> 8993521

The current status of irinotecan (CPT-11) in the United States.

M L Rothenberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8993521     DOI： 10.1111/j.1749-6632.1996.tb26397.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  5 in total

Review 1.  Irinotecan pharmacogenomics.

Authors:  Sharon Marsh; Janelle M Hoskins
Journal:  Pharmacogenomics       Date:  2010-07       Impact factor: 2.533

2.  Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma.

Authors:  J A Ajani; R Pazdur; P Dumas; J Fairweather
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

Review 3.  Camptothecins: a review of their chemotherapeutic potential.

Authors:  Hulya Ulukan; Peter W Swaan
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects.

Authors:  W E Hardman; M P Moyer; I L Cameron
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

Review 5.  Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.

Authors:  Luca Falzone; Salvatore Salomone; Massimo Libra
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.